Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990040/S036

TRUFILL n-BCA Liquid Embolic System

Cerenovus, Inc. · Decision date Aug 22, 2025

FDA DECISIONP990040/S036

What did the FDA decide?

FDA records P990040/S036 as a supplement to PMA P990040, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 22, 2025.

FDA approval order statement

approval for an alternative identification method for the ethiodized oil component
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Aug 22, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P990040/S036
Regulatory pathway
PMA supplement
Product code
KGG
Decision code
OK30
Decision date
Aug 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: tissue adhesive for use in embolization of brain arteriovenous malformations.

Product code
KGG
FDA device class
3

For the original device and its historical approval scope, see PMA P990040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P990040 · Original PMA

    TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM

  2. P990040/S036 received

    Application receipt date recorded by FDA.

  3. P990040/S036 · FDA decision

    30-Day Notice

  4. P990040/S034 · Related supplement

    TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural Set

  5. P990040/S038 · Related supplement

    TRUFILL n-BCA Liquid Embolic System

  6. P990040/S037 · Related supplement

    TRUFILL n-BCA Liquid Embolic System

Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990040

Product / regulatory recordCompanyPathwayDecision dateSource
Cerenovus, Inc.PMA approvalSep 25, 2000FDA
Cerenovus, Inc.PMA supplementDec 16, 2025FDA
Cerenovus, Inc.PMA supplementMay 26, 2026FDA
Cerenovus, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cerenovus, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6303 Waterford District Dr., Suite 315, Miami, FL, 33126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records